Goy, A. Et Al. 2013. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology , vol.31, no.29 , 3688-95.

Goy, A., Sinha, R., Williams, M. E., Besisik, S., Drach, J., Ramchandren, R., ... Zhang, L.(2013). Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology , vol.31, no.29, 3688-95.

Goy, Andre Et Al. "Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.," Journal of clinical oncology : official journal of the American Society of Clinical Oncology , vol.31, no.29, 3688-95, 2013

Goy, Andre Et Al. "Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.." Journal of clinical oncology : official journal of the American Society of Clinical Oncology , vol.31, no.29, pp.3688-95, 2013

Goy, A. Et Al. (2013) . "Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.." Journal of clinical oncology : official journal of the American Society of Clinical Oncology , vol.31, no.29, pp.3688-95.

@article{article, author={Andre Goy Et Al. }, title={Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year=2013, pages={3688-95} }